Please check your internet connection and try again.
# Arsilodx
## Overview
Arsilodx (fesoterodine fumarate) is a muscarinic receptor antagonist. It works by relaxing the bladder muscle, which can help reduce the urgency, frequency, and incontinence associated with overactive bladder (OAB).
## Primary Indications
* Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
## Adult Dosing
* **Starting Dose:** 4 mg orally once daily.
* **Maximum Dose:** 8 mg orally once daily.
Dosing may be adjusted based on individual response and tolerability.
## Pediatric Dosing
Fesoterodine fumarate is not approved for use in pediatric patients. Safety and efficacy have not been established.
## Dose Adjustments
* **Renal Impairment:**
* Mild to moderate (CrCl 30-80 mL/min): Start with 4 mg orally once daily. Maximum dose is 4 mg once daily.
* Severe (CrCl <30 mL/min): Start with 4 mg orally once daily. Maximum dose is 4 mg once daily.
* **Hepatic Impairment:**
* Moderate (Child-Pugh B): Start with 4 mg orally once daily. Maximum dose is 4 mg once daily.
* Severe (Child-Pugh C): Use is not recommended.
* **CYP3A4 Inhibitors:** Avoid concomitant use. If coadministration is necessary, the dose should not exceed 4 mg once daily.
## Contraindications
* Patients with urinary retention, gastric retention, or decreased gastrointestinal motility.
* Patients with uncontrolled narrow-angle glaucoma.
* Patients with known hypersensitivity to fesoterodine, its metabolites (e.g., rovaberdine), or any of its ingredients.
## Adverse Effects
* **Common:** Dry mouth, constipation, urinary tract infection, dizziness, fatigue.
* **Serious:** Urinary retention, angioedema, blurred vision, cognitive impairment, potential exacerbation of narrow-angle glaucoma.
## Key Drug Interactions
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** Increased fesoterodine exposure and potential for increased adverse effects. Avoid coadministration or use lower fesoterodine doses.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease fesoterodine efficacy.
* **Other Anticholinergic Agents:** May potentiate effects on bladder and gastrointestinal smooth muscle, increasing the risk of adverse effects like urinary retention and constipation.
* **Tamsulosin:** Coadministration with fesoterodine has shown increased risk of hypotension.
## Monitoring
* Assess for urinary retention, especially in patients with risk factors.
* Monitor for signs of hypersensitivity reactions.
* Monitor for anticholinergic side effects (e.g., dry mouth, constipation, visual disturbances, cognitive changes).
* Assess for potential drug interactions, particularly with CYP3A4 inhibitors.
## Clinical Pearls
* Fesoterodine is a prodrug converted to its active metabolite, rovaberdine.
* Onset of action may be gradual; full benefit may not be seen for up to 12 weeks.
* Consider alternative management strategies for patients with significant gastrointestinal or genitourinary comorbidities.
* Dosing adjustments are crucial for patients with renal or hepatic impairment, and those taking CYP3A4 inhibitors.
***
*Disclaimer: This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines for complete details before initiating therapy.*
